Stockscreener 앱 받기
2.77
7.36%
-0.22
시간 외 거래:
2.79
0.02
+0.72%
전일 마감가:
$2.99
열려 있는:
$2.96
하루 거래량:
2.31M
Relative Volume:
0.59
시가총액:
$356.41M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-2.5888
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
-6.42%
1개월 성능:
-29.34%
6개월 성능:
-50.89%
1년 성능:
-15.81%
1일 변동 폭
$2.75
$3.005
1주일 범위
$2.75
$3.11
52주 변동 폭
$2.75
$9.97
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.77 | 356.41M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
HUMA stock touches 52-week low at $2.81 amid market shifts By Investing.com - Investing.com South Africa
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Nasdaq
Humacyte’s Symvess: A Transformative Solution in Vascular Trauma Care with Strong Market Potential - TipRanks
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics - The Manila Times
Humacyte Announces Economic Value of Symvess in Budget Impact Model Publication - Nasdaq
New Study: Humacyte's Symvess Cuts Trauma Center Costs by $33,000 Per Patient - StockTitan
Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating - TipRanks
Humacyte (NASDAQ:HUMA) Earns Buy Rating from D. Boral Capital - Defense World
Rhumbline Advisers Acquires 5,005 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Benchmark maintains Humacyte stock Buy rating, $17 target - Investing.com India
Benchmark maintains Humacyte stock Buy rating, $17 target By Investing.com - Investing.com South Africa
Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Average Target Price from Analysts - Defense World
Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research -March 06, 2025 at 09:16 am EST - Marketscreener.com
Humacyte, Trestle Biotherapeutics announce research collaboration - TipRanks
Can This Groundbreaking Biotech Partnership Solve the Kidney Transplant Crisis? - StockTitan
Trestle Bio Announces Research Collaboration with Humacyte - The Bakersfield Californian
Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 - The Manila Times
Will Humacyte's First-in-Class Bioengineered Vessel Transform Trauma Care? Investors to Get Answers - StockTitan
Atria Wealth Solutions Inc. Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Buy Rating for Humacyte Driven by Symvess Launch and Economic Advantages - TipRanks
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Humacyte, Inc. (HUMA) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - MSN
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Humacyte's Presentation at TD Cowen Conference Reveal New Bioengineered Tissue Breakthroughs? - StockTitan
Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System - Marketscreener.com
Humacyte secures patent for bioreactor system until 2040 By Investing.com - Investing.com South Africa
Humacyte secures patent for bioreactor system until 2040 - Investing.com India
Humacyte announces issuance of U.S. patent covering Symvess manufacturing - TipRanks
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues - The Manila Times
Can Humacyte's New Patent Transform Trauma Care? FDA-Approved Tissue Tech Now Protected Until 2040 - StockTitan
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineHUMA - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out - ACCESS Newswire
Promising Commercial Launch and Strategic Positioning Drive Buy Rating for Humacyte - TipRanks
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Humacyte announces commercial launch of Symvess™ (acellular tissue engineered vessel-tyod) for extremity vascular trauma - PharmaLive
FDA approves Humacyte's Symvess for vascular injuries By Investing.com - Investing.com South Africa
Humacyte announces commercial launch of Symvess - TipRanks
FDA approves Humacyte’s Symvess for vascular injuries - Investing.com India
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma - The Manila Times
FDA approves Humacyte's Symvess for vascular injuries - Investing.com
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity - EIN News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - ACCESS Newswire
Lost Money on Humacyte, Inc. (HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven? - Yahoo Finance UK
Humacyte stock rallies 19% on FDA RMAT designation - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):